文献速递血液净化与透析

植入式血管支撑装置用于动静脉内瘘:一项随机对照试验

An Implanted Blood Vessel Support Device for Arteriovenous Fistulas: A Randomized Controlled Trial.
PubMed 文献 · Am J Kidney Dis · 2019-08-22

本研究为前瞻性随机对照多中心试验,纳入40例拟行头臂动静脉内瘘的肾衰竭患者,比较VasQ植入物与无植入物的安全性和疗效。结果显示无严重装置相关不良事件,治疗组3个月和6个月静脉管径显著更大,6个月功能通畅率显著更高。

要点

  • VasQ植入物未观察到严重装置相关不良事件。
  • 治疗组3个月和6个月头静脉管径显著大于对照组。
  • 治疗组6个月功能通畅率显著高于对照组。

核心结论

  • VasQ外部支撑头臂动静脉内瘘未检测到安全信号。
  • 装置在3个月和6个月时获得更高的功能通畅率和静脉管径。

研究设计与样本

  • 前瞻性、随机、对照、多中心研究。
  • 40例连续肾衰竭患者,来自英国和以色列4个血管通路中心。

主要发现

  • 未观察到严重装置相关不良事件。
  • 3个月成熟率治疗组85% vs 对照组80%,6个月初级通畅率80% vs 66%,均无显著差异。
  • 3个月静脉管径治疗组8.27±2.2mm vs 对照组6.69±1.8mm(P=0.03)。
  • 6个月静脉管径治疗组9.6±2.5mm vs 对照组7.56±2.7mm(P=0.03)。
  • 6个月功能通畅率治疗组100% vs 对照组56%(P=0.01)。

关键数值与推荐

  • 3个月成熟定义为头静脉直径≥5mm且流量≥500mL/min。
  • 功能累积通畅定义为研究期间接受透析者中至少三分之二的透析次数成功双针穿刺持续1个月。

临床怎么用

  • VasQ植入物可安全用于头臂动静脉内瘘手术。
  • 该装置可能改善静脉管径和功能通畅率,但需更大样本验证。

局限性

  • 样本量小,次要终点统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Reducing turbulent blood flow through dialysis arteriovenous fistulas (AVFs) and radial stretching of their venous wall may attenuate hyperplasia and stenosis and improve AVF outcomes in hemodialysis patients. The goal of this study was to evaluate the safety and efficacy of the VasQ implant, which intervenes on these mechanisms by physically supporting the surgical arteriovenous anastomosis. STUDY DESIGN: Prospective, randomized, controlled, multicenter study. SETTINGS & PARTICIPANTS: 40 consecutive patients with kidney failure referred for creation of a brachiocephalic fistula in 4 vascular access centers in the United Kingdom and Israel. INTERVENTIONS: AVF surgical creation with placement of the VasQ implant (treatment) versus AVF placement without the implant (control). OUTCOMES: Safety assessed as percentage of severe device-related adverse events was the primary outcome. Secondary outcomes were efficacy assessments including: (1) AVF maturation at 3 months, defined as cephalic vein diameter≥5mm and flow≥500mL/min; (2) functional cumulative patency, defined as successful 2-needle cannulation for two-thirds or more of all dialysis runs for 1 month in study participants receiving dialysis; (3) cephalic vein diameter and blood flow; and (4) primary and cumulative patency at 6 months. RESULTS: No severe device-related adverse events were observed. There was no significant difference in maturation at 3 months or primary patency at 6 months between treatment and control (85% vs 80% and 80% vs 66%). Significantly larger vein luminal diameters were observed in the treatment group versus controls at 3 and 6 months (8.27±2.2 vs 6.69±1.8mm [P=0.03] and 9.6±2.5 vs 7.56±2.7mm [P=0.03]). Functional patency at 6 months was significantly greater in the treatment group (100% vs 56% [P = 0.01]). LIMITATIONS: Small sample size, limited power for secondary end points. CONCLUSIONS: No safety signals were detected for the VasQ external support of brachiocephalic AVFs. Higher functional patency and vein luminal diameters were achieved with the device at 3 and 6 months. VasQ may safely intervene on mechanisms associated with the disturbed hemodynamic profile in the juxta-anastomotic region. FUNDING: Funded by Laminate Medical Technologies Ltd. TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT02112669.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Karydis N, Bevis P, Beckitt T, et al. An Implanted Blood Vessel Support Device for Arteriovenous Fistulas: A Randomized Controlled Trial. Am J Kidney Dis. 2019. PMID: 31447072. doi:10.1053/j.ajkd.2019.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。